Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Sunitinib with Paclitaxel/Carboplatin in TNBC
NCT00887575Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Jun 2009
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunitinib in triple-negative breast cancer (TNBC) (3 arms), sponsored by SCRI Development Innovations. Primary endpoints: Maximum Tolerated Dose and Pathologic Complete Response. Started Jun 2009; status: completed.
02
Drugs
sunitinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00887575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00887575.